Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Market Cap 158B 2,718B 136B 125B 118B 221B 14,935B 223B 1,481B 577B 7,314B 593B 580B 25,346B P/E Ratio 2026 *
-45.6x
P/E Ratio 2027 * 16.5x
Enterprise Value 168B 2,882B 144B 133B 125B 234B 15,839B 237B 1,571B 612B 7,757B 629B 615B 26,881B EV / Sales 2026 *
5.5x
EV / Sales 2027 * 4.86x
Free-Float
99.87%
Yield 2026 *
2.55%
Yield 2027 * 2.61%
1 day-6.44%
1 week-6.44%
Current month-9.33%
1 month-6.88%
3 months-18.46%
6 months-1.27%
Current year-4.73%
1 month 2,117.15
Extreme 2117.15
2,335
Current year 2,117.15
Extreme 2117.15
2,618.71
1 year 2,025.32
Extreme 2025.32
2,618.71
3 years 1,046.71
Extreme 1046.71
2,618.71
5 years 1,046.71
Extreme 1046.71
2,618.71
10 years 1,046.71
Extreme 1046.71
2,618.71
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5-day change 1-year change 3-year change Capi.($)
-6.44%-6.44% - - 158B
-0.61%-1.94%+39.00%+150.72% 1,001B
-0.20%-0.77%+51.51%+43.20% 566B
+0.40%-1.31%+16.56%+60.47% 393B
+0.64%+2.29%+24.04%+16.53% 326B
+0.23%+0.59%+25.29%+31.80% 276B
+0.63%-0.88%+25.17%+14.60% 277B
+4.28%+1.08%-41.36%-47.15% 193B
-0.77%+0.95%+17.69%+51.46% 188B
+0.15%+1.32%+6.72%-35.00% 148B
Average -0.14%+0.35%+18.29%+31.85% 374.14B
Weighted average by Cap. +0.04%-0.41%+27.57%+63.16%

Financials

2026 *2027 *
Net sales 30.48B 524B 26.27B 24.19B 22.71B 42.64B 2,882B 43.09B 286B 111B 1,411B 114B 112B 4,890B 32.45B 558B 27.97B 25.75B 24.18B 45.4B 3,068B 45.88B 304B 119B 1,502B 122B 119B 5,207B
Net income -3.37B -58.02B -2.91B -2.68B -2.51B -4.72B -319B -4.77B -31.63B -12.32B -156B -12.66B -12.39B -541B 9.6B 165B 8.28B 7.62B 7.16B 13.43B 908B 13.58B 90.05B 35.08B 445B 36.04B 35.27B 1,541B
Net Debt 9.57B 165B 8.25B 7.59B 7.13B 13.39B 905B 13.53B 89.72B 34.95B 443B 35.91B 35.15B 1,535B -96.43M -1.66B -83.1M -76.53M -71.85M -135M -9.12B -136M -904M -352M -4.46B -362M -354M -15.47B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
127.23USD
Average target price
157.57USD
Spread / Average Target
+23.85%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!